Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Comparing 16 To 18 Weeks Of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), Or Anastrozole (1 mg) In Postmenopausal Women With Clinical Stage II And III Estrogen Receptor Positive Breast Cancer COHORT B.

Next Previous
Trial Profile

A Randomized Phase III Trial Comparing 16 To 18 Weeks Of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), Or Anastrozole (1 mg) In Postmenopausal Women With Clinical Stage II And III Estrogen Receptor Positive Breast Cancer COHORT B.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms Z1031

    • Most Recent Events

    • 08 Jun 2021 Results of a sensitivity to endocrine therapy index analysis presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 04 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top